CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Other Events
On September 16, 2019, CytoSorbents Corporation issued a press release announcing that the Hannover Medical School in Germany will begin the CYTORELEASE clinical study, the first clinical study to evaluate the use of CytoSorb® in treating Cytokine Release Syndrome and CAR-related Encephalopathy Syndrome, following CAR-T immunotherapy.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
|Exhibit No.||Exhibit Name|
|99.1||CytoSorbents Corporation Press Release dated September 16, 2019|
Cytosorbents Corp Exhibit
EX-99.1 2 tv529574_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence MONMOUTH JUNCTION,…
To view the full exhibit click
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.